Apple: Still Early For The Holy Grail


  • Apple continues working on turning the Apple Watch into a medical device.
  • The tech giant has made progress on a glucose monitoring system with the signs the concept works, but the company needs to scale the product into a wearable form factor.
  • The stock is already priced for a Holy Grail new product, while investors should buy the stock when a new medical device is a bonus for a cheap stock.
  • Apple shouldn’t already trade at 25x FY23 EPS targets.

Doctor wear gloves is using lancet on a patient"s finger.

CHAYAKORN MAMUANG/iStock via Getty Images

The holy grail of the Apple (NASDAQ:AAPL) Watch is turning the product into a medical device. The tech company has a promising new use for the watch, but the market has already hyped the entry

G7 pic

Source: Dexcom

Wearables table

Source: BusinessofApps

Apple Watch

Source: Apple

Earnings estimates table

Source: Seeking Alpha

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: The information contained herein is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock, you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.

If you’d like to learn more about how to best position yourself in under valued stocks mispriced by the market heading into a 2023 Fed pause, consider joining Out Fox The Street

The service offers model portfolios, daily updates, trade alerts and real-time chat. Sign up now for a risk-free, 2-week trial to start finding the next stock with the potential to generate excessive returns in the next few years without taking on the out sized risk of high flying stocks. 

Leave a Reply

Your email address will not be published. Required fields are marked *